Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

Lancet Oncol. 2022 Apr;23(4):e157. doi: 10.1016/S1470-2045(22)00154-1.

¹ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
² Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
³ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland; Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: Fernanda.Herrera@chuv.ch.

No abstract available

Publication types